γδ T cells and epigenetic drugs: A useful merger in cancer immunotherapy?
γδ T cells and epigenetic drugs: A useful merger in cancer immunotherapy?
复制标题
DOI：
10.1080/2162402x.2015.1006088
复制
发表时间：
2015-06-01
期刊：
影响因子：
7.2
通讯作者：
Kabelitz, Dieter
中科院分区：
文献类型：
--
作者：
Bhat, Jaydeep;Kabelitz, Dieter
在癌症患者中基于T细胞的免疫策略迄今为止成功有限。靶向包括组蛋白乙酰化和DNA甲基化的表观遗传机制的药物触发肿瘤细胞中的细胞死亡，但另外具有免疫调节活性。在这里，我们讨论了在癌症免疫治疗中结合这两种策略的潜在好处。
T cell-based immunotherapeutic strategies in cancer patients are as yet of limited success. Drugs targeting epigenetic mechanisms including histone acetylation and DNA methylation trigger cell death in tumor cells but in addition have immunomodulatory activity. Here, we discuss the potential benefit of combining both strategies in cancer immunotherapy.